As pharmacological inhibition of SATB2/CBP function markedly inhibited GBM tumor growth, therapeutic targeting of the SATB2/CBP‐FOXM1 signaling axis may offer an effective strategy to significantly improve therapeutic efficacy for GBMs and prolong survival of the patients. Here, SATB2 is linked to glioblastoma.